These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 23078651)

  • 21. Current use of pimobendan in canine patients with heart disease.
    Boswood A
    Vet Clin North Am Small Anim Pract; 2010 Jul; 40(4):571-80. PubMed ID: 20610012
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of atrial fibrillation as a prognostic factor in doberman pinschers with dilated cardiomyopathy and congestive heart failure.
    Friederich J; Seuß AC; Wess G
    Vet J; 2020 Oct; 264():105535. PubMed ID: 33012438
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of oral administration of pimobendan in cats with heart failure.
    Gordon SG; Saunders AB; Roland RM; Winter RL; Drourr L; Achen SE; Hariu CD; Fries RC; Boggess MM; Miller MW
    J Am Vet Med Assoc; 2012 Jul; 241(1):89-94. PubMed ID: 22720992
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of pimobendan in 170 cats (2006-2010).
    Macgregor JM; Rush JE; Laste NJ; Malakoff RL; Cunningham SM; Aronow N; Hall DJ; Williams J; Price LL
    J Vet Cardiol; 2011 Dec; 13(4):251-60. PubMed ID: 22030289
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
    Smith PJ; French AT; Van Israël N; Smith SG; Swift ST; Lee AJ; Corcoran BM; Dukes-McEwan J
    J Small Anim Pract; 2005 Mar; 46(3):121-30. PubMed ID: 15789807
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of pimobendan and N-terminal probrain natriuretic peptide in the treatment of pulmonary hypertension secondary to degenerative mitral valve disease in dogs.
    Atkinson KJ; Fine DM; Thombs LA; Gorelick JJ; Durham HE
    J Vet Intern Med; 2009; 23(6):1190-6. PubMed ID: 19780931
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of a fixed-dose combination of benazepril and pimobendan in dogs with congestive heart failure: a randomized non-inferiority clinical trial.
    King JN; Hirakawa A; Sonobe J; Otaki H; Sakakibara N; Seewald W; Forster S
    J Vet Sci; 2018 Jan; 19(1):117-128. PubMed ID: 28693297
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of treatment with pimobendan in dogs with preclinical mitral valve disease - a placebo-controlled double-blinded crossover study.
    Klein S; Nolte I; Rumstedt K; Sehn M; Raue JF; Weiner F; Treese JS; Beyerbach M; Bach JP
    BMC Vet Res; 2021 Sep; 17(1):310. PubMed ID: 34563187
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival and echocardiographic data in dogs with congestive heart failure caused by mitral valve disease and treated by multiple drugs: a retrospective study of 21 cases.
    de Madron E; King JN; Strehlau G; White RV
    Can Vet J; 2011 Nov; 52(11):1219-25. PubMed ID: 22547843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study).
    Effects of Pimobendan on Chronic Heart Failure Study (EPOCH Study)
    Circ J; 2002 Feb; 66(2):149-57. PubMed ID: 11999639
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical findings and survival time in dogs with advanced heart failure.
    Beaumier A; Rush JE; Yang VK; Freeman LM
    J Vet Intern Med; 2018 May; 32(3):944-950. PubMed ID: 29635788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial.
    Iwanuk N; Nolte I; Wall L; Sehn M; Raue J; Pilgram A; Rumstedt K; Bach JP
    BMC Vet Res; 2019 Jul; 15(1):237. PubMed ID: 31288807
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of pimobendan on the clinical outcome and survival of cats with non-taurine responsive dilated cardiomyopathy.
    Hambrook LE; Bennett PF
    J Feline Med Surg; 2012 Apr; 14(4):233-9. PubMed ID: 22412159
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency.
    Atkins CE; Keene BW; Brown WA; Coats JR; Crawford MA; DeFrancesco TC; Edwards NJ; Fox PR; Lehmkuhl LB; Luethy MW; Meurs KM; Petrie JP; Pipers FS; Rosenthal SL; Sidley JA; Straus JH
    J Am Vet Med Assoc; 2007 Oct; 231(7):1061-9. PubMed ID: 17916031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heart rate turbulence after ventricular premature beats in healthy Doberman pinschers and those with dilated cardiomyopathy.
    Harris JD; Little CJL; Dennis JM; Patteson MW
    J Vet Cardiol; 2017 Oct; 19(5):421-432. PubMed ID: 28958795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of pimobendan in the management of heart failure.
    Fuentes VL
    Vet Clin North Am Small Anim Pract; 2004 Sep; 34(5):1145-55. PubMed ID: 15325474
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure.
    Katz SD; Kubo SH; Jessup M; Brozena S; Troha JM; Wahl J; Cohn JN; Sonnenblick EH; LeJemtel TH
    Am Heart J; 1992 Jan; 123(1):95-103. PubMed ID: 1729854
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of prespecified therapy escalation on plasma NT-proBNP concentrations in dogs with stable congestive heart failure due to myxomatous mitral valve disease.
    Hezzell MJ; Block CL; Laughlin DS; Oyama MA
    J Vet Intern Med; 2018 Sep; 32(5):1509-1516. PubMed ID: 30216549
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial.
    Lubsen J; Just H; Hjalmarsson AC; La Framboise D; Remme WJ; Heinrich-Nols J; Dumont JM; Seed P
    Heart; 1996 Sep; 76(3):223-31. PubMed ID: 8868980
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group.
    Kubo SH; Gollub S; Bourge R; Rahko P; Cobb F; Jessup M; Brozena S; Brodsky M; Kirlin P; Shanes J
    Circulation; 1992 Mar; 85(3):942-9. PubMed ID: 1537130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.